Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
Contents:; 1: Basis of Carcinogenesis; 2: Epidemiology and Prevention; 3: Evidence-Based Nursing in Basic Anticancer Treatment: Management of the Most Important Side Effects; 4: The Patients? Journey with Targeted Therapies; 5: Immunotherapy: New Challenges for Nursing; 6: Robotic Surgery; 7: Relat…
Contents:; Physical activity and cancer survival -- Promoting physical activity for cancer survivors -- FITT principle for physical activity -- Assessing readiness for physical activity -- Assessing readiness for physical activity : physical -- Considerations -- Evaluating tolerance and adherence t…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available | ||
c.2 BC Cancer Agency VIC Library | Available | ||
c.1 BC Cancer Agency CN Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
Building capacity for cancer treatment in low-income countries with particular reference to East Africa by Ian Magrath and Simon Sutcliffe.
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; Chapter 1 -- Translation in Immunology: The Role of Translational Biomarkers to Guide Clinical Use of Immunotherapy for Cancer -- Chapter 2 Monoclonal Antibody Therapy -- Chapter 3 Somatic Mutations and Immunotherapy -- Chapter 4 Checkpoint Blockade -- Chapter 5 Myeloid Leukemia…
Table of Contents:; 1. HISTORY OF IMMUNOTHERAPY -- 2. PRINCIPLES OF IMMUNOLOGY AND IMMUNOTHERAPY -- 3. CYTOKINES IN IMMUNOTHERAPY -- 4. IMMUNE CHECKPOINT INHIBITORS -- 5. BACILLUS CALMETTE-GUÉRIN - 6. ORAL IMMUNOMODULATORY AGENTS --7. ACTIVE IMMUNITY: VACCINE THERAPY -- 8. PASSIVE/ADOPTIVE IMMUNOTH…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available | ||
c.1 BC Cancer Agency CN Library Missing | Available | ||
c.2 BC Cancer Agency SUR Library | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.2 BC Cancer Agency VAN Library | Available | ||
c.3 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Library | Available |
The series is primarily intended to document the disease classifications used in the Population Health Impact of Disease in Canada (PHI) research program and help researchers to understand how the PHI estimates were calculated. It is also of interest to health professionals, advocacy groups, and in…
c.1 BC Cancer Agency VAN Library | Available |